Eli Lilly (LLY) and Company announced that the U.S. FDA approved a single-injection, once-monthly maintenance regimen (200 mg/2 mL) of Omvoh for subcutaneous use in adults with moderately to severely active ulcerative colitis.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly’s Latest Study on Abemaciclib: A Potential Game-Changer in Pediatric Cancer Treatment
- Eli Lilly’s Orforglipron Study: A Potential Game-Changer in Diabetes Treatment
- Eli Lilly Withdraws Key Obesity and Diabetes Study: Market Implications
- Eli Lilly’s Obesity Study: A Potential Game-Changer in Calorie Management
- Eli Lilly’s Orforglipron Study: A New Hope for Type 2 Diabetes Management